© 2020 MJH Life Sciences and OncLive. All rights reserved.
August 13, 2020
John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.
May 14, 2020
John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.
May 13, 2020
May 07, 2020
John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses the shift toward precision medicine in large cell lymphoma.